Posts

Posted on

Lipocine Provides New Regulatory Update on TLANDO™

PR Newswire

SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it is continuing to work towards taking action on the TLANDO New Drug Application (“NDA”) during the week of December 7, 2020.  However, the Company cannot assure that the FDA will act in that time frame. 

TLANDO is the Company’s oral testosterone product candidate for testosterone replacement therapy (“TRT”) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.

About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. Lipocine has resubmitted its NDA to the FDA for TLANDO and it is currently under review by the FDA.  LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH.  LPCN 1144 is currently being studied in a Phase 2 clinical study.  TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate, with end of phase 2 meeting completed, indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.

Forward-Looking Statements
This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine’s product candidates and related clinical trials, the timing of completion of clinical trials, the expected timing of an FDA decision with regards to TLANDO, and the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not act on TLANDO in the time frame expected and the risk that the FDA will not approve TLANDO or any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-provides-new-regulatory-update-on-tlando-301186755.html

SOURCE Lipocine Inc.

Posted on

Breeze Airways and Utah Valley University Partner For New Flight Attendant Program

Utah Valley University, Orem, Utah, Dec. 04, 2020 (GLOBE NEWSWIRE) — Breeze Airways, the new airline start-up, pending FAA and DOT approval, from JetBlue founder David Neeleman, has partnered with Utah Valley University to create an innovative flight attendant training program. Breeze will hire qualified UVU students as flight attendants and will simultaneously provide them with a path to a college degree through the University.

According to program guidelines, qualified in-state, full-time, degree-seeking students at UVU will receive full tuition reimbursement, and out-of-state students can receive up to $6,000 per year. Participants must be accepted as full-time students and complete at least 30 credit hours per year to qualify. All university classes will be online.

“As we prepare the ‘world’s nicest airline’ for launch in 2021, we’re looking for student team members who will help us in that quest,’” said David Neeleman, Breeze Airways founder and CEO. “Everyone wins through this partnership. Breeze hires outstanding student team members who receive real-world experience and a college degree.”

Students must also be at least 20 years old, willing to relocate to bases where Breeze needs them, and work 15 days per month. They must be accepted to UVU before their initial training date with the airline. Other benefits include monthly salary, paid housing, transportation to and from the airport for work, and one paid trip home per month.

“UVU is extremely pleased with the Breeze Airways partnership,” said David McEntire, UVU’s dean of the College of Health and Public Service, of which aviation is a part. “It is clearly a wonderful opportunity for our students and the airline. Our college and department leaders cannot express our gratitude enough for this innovative collaboration.”

Students must maintain a minimum GPA of 3.0 and complete the initial flight attendant training program in Salt Lake City before tuition will be covered. University classes will be limited during training.



Scott Trotter
Utah Valley University
8014196860
[email protected]

Posted on

Lattice Semiconductor Wins 2020 GSA Most Respected Semiconductor Company Award

Lattice Semiconductor Wins 2020 GSA Most Respected Semiconductor Company Award

HILLSBORO, Ore.–(BUSINESS WIRE)–Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced the company won a Global Semiconductor Alliance (GSA) 2020 Most Respected Public Semiconductor Company Award. The award recognizes companies for their vision, technology, and market leadership as determined by votes from GSA members.

Jim Anderson, President and Chief Executive Officer at Lattice, said, “On behalf of the entire Lattice Semiconductor team, I thank the GSA for this recognition. I also want to congratulate my Lattice teammates on this award and on their creativity, dedication, and outstanding teamwork. We look forward to continuing to unlock the full potential of Lattice as we accelerate adoption of Lattice’s low power FPGAs and solutions stacks across our target markets.”

This year’s virtual ceremony was attended by nearly 1,500 global executives in the semiconductor and technology industries. Members of the GSA represent 70 percent of the $450B+ global semiconductor industry.

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo, or Youku.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

MEDIA CONTACT:

Bob Nelson

Lattice Semiconductor

408-826-6339

[email protected]

INVESTOR CONTACT:

Rick Muscha

Lattice Semiconductor

408-826-6000

[email protected]

KEYWORDS: Oregon United States North America

INDUSTRY KEYWORDS: Semiconductor Data Management Technology Networks Internet Hardware

MEDIA:

Logo
Logo
Posted on

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Northern Dynasty Minerals Ltd. – NAK

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Northern Dynasty Minerals Ltd. – NAK

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Northern Dynasty Minerals Ltd. (NYSE: NAK) between December 21, 2017 through November 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Northern Dynasty investors under the federal securities laws.

To join the Northern Dynasty class action, go to http://www.rosenlegal.com/cases-register-1996.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company’s Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (2) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (3) as a result, the Company’s permit applications for the Pebble Project would be denied by the U.S. Army Corps of Engineers; and (4) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 2, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1996.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Trepont Acquisition Corp I Announces Closing of $230 Million Initial Public Offering

Trepont Acquisition Corp I Announces Closing of $230 Million Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Trepont Acquisition Corp I (the “Company”) announced the closing today of its initial public offering of 23,000,000 units at a price of $10.00 per unit, including an additional 3,000,000 units sold pursuant to the full exercise of the underwriters’ over-allotment option. The units began trading on the New York Stock Exchange (“NYSE”) under the ticker symbol “TACA.U” on December 2, 2020. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on NYSE under the symbols “TACA” and “TACA.WS,” respectively.

The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on businesses that operate in enterprise & disruptive software, communications, artificial intelligence, machine learning, data analytics 5G, IoT, services and related sectors. Our management team is led by our Co-Founders Arun Sarin, the Chairman of the Board, who was previously Chief Executive Officer of Vodafone Group plc, and Ori Sasson, our Chief Executive Officer and Chief Financial Officer, who was previously the founder and Chief Executive Officer of Scopus and Chief Executive Officer of Genesys Telecommunications Laboratories. Our Co-Founders have over six decades of combined experience leading, advising and investing in public and private technology and telecommunications businesses.

Credit Suisse is acting as the sole book-running manager of the offering. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, Telephone: 1-800-221-1037, Email: [email protected].

A registration statement relating to the securities has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 1, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:

For inquiries:

Lee Fan at [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Professional Services Telecommunications Finance

MEDIA:

Posted on

AM Best Affirms Credit Ratings of Arch Capital Group Ltd. And Its Subsidiaries

AM Best Affirms Credit Ratings of Arch Capital Group Ltd. And Its Subsidiaries

OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “aa-” of Arch Reinsurance Ltd.(Arch) (Bermuda) and its strategic affiliates. Concurrently, AM Best has affirmed the Long-Term ICR of “a-” and the Long-Term Issue Credit Ratings (Long-Term IRs) of Arch Capital Group Ltd.(Arch Capital) (Bermuda) [NASDAQ: ACGL], the ultimate holding company; Arch Capital Group (US) Inc (Delaware); and Arch Capital Finance LLC(Delaware). (See below for a detailed listing of the companies and ratings.) The outlook of these Credit Ratings (ratings) is stable.

The ratings of Arch reflect the group’s balance sheet strength, which AM Best categorizes as strongest, as well as its strong operating performance, favorable business profile and appropriate enterprise risk management.

The ratings are based on Arch’s historically strong operating performance, as well as its balance sheet strength, as measured by Best’s Capital Adequacy Ratio, and strong management team. Arch continues to perform favorably on most operating metrics while maintaining a strong risk-adjusted capital position, despite a significant Stressed Ultimate Loss, as calculated according to AM Best’s “Evaluating Mortgage Insurance” criteria procedure, and low risk-adjusted investment market returns. Arch has demonstrated that it will actively manage the (re)insurance cycles.

The stable outlooks reflect AM Best’s expectations that the group’s strongest level of balance sheet strength will continue to be supported by strong and stable operating performance, favorable reserve development, diverse business profile and well-defined ERM program.

AM Best also recognizes that the mortgage insurance business relies heavily on financial models that can vary from actual results. AM Best utilized a conservative stress scenario for Arch’s mortgage insurance book of business when calculating stress-tested risk-adjusted capitalization. Mortgage insurance products have a relatively long exposure period when compared with most of Arch’s current property/casualty insurance and reinsurance products, which can be characterized as medium tail on average. AM Best considered long-term sources of liquidity in the evaluation of these potential tail risk events.

The FSR of A+ (Superior) and the Long-Term ICRs of “aa-” have been affirmed with stable outlooks for Arch Reinsurance Ltd. and its following affiliates:

  • Arch Reinsurance Company
  • Arch Insurance Company
  • Arch Specialty Insurance Company
  • Arch Property Casualty Insurance Company
  • Arch Indemnity Insurance Company
  • Arch Insurance Canada Ltd.
  • Alwyn Insurance Company Limited
  • Arch Insurance (UK) Limited

The following Long-Term IRs have been affirmed with stable outlooks:

Arch Capital Group Ltd.—

— “a-” on $300 million 7.35% senior unsecured notes, due 2034

— “bbb” on $450 million 5.25% non-cumulative preferred shares, Series C

— “bbb” on $330 million 5.45% non-cumulative preferred shares, Series C

Arch Capital Group (US) Inc(guaranteed by Arch Capital Group Ltd.)—

— “a-” on $500 million 5.144% senior unsecured notes, due 2043

Arch Capital Finance LLC(guaranteed by Arch Capital Group Ltd.)—

— “a-” on $500 million 4.011% senior unsecured notes, due 2026

— “a-” on $450 million 5.031% senior unsecured notes, due 2046

The following indicative Long-Term IRs under the existing shelf registration have been affirmed with stable outlooks:

Arch Capital Group Ltd.—

— “a-” on senior unsecured debt

— “bbb+” on subordinated debt

— “bbb” on preferred stock

Arch Capital Group (US) Inc(guaranteed by Arch Capital Group Ltd.)—

— “a-” on senior unsecured debt

— “bbb+” on subordinated debt

— “bbb” on preferred stock

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper media use of Best’s Credit Ratings and AM Best press releases, please view Guide for Media – Proper Use of Best’s Credit Ratings and AM Best Rating Action Press Releases.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2020 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Darian Ryan, CPA

Senior Financial Analyst

+1 908 439 2200, ext. 5449

[email protected]

Christopher Sharkey

Manager, Public Relations

+1 908 439 2200, ext. 5159

[email protected]

Steven Chirico, CPA

Director

+1 908 439 2200, ext. 5087

[email protected]

Jim Peavy

Director, Public Relations

+1 908 439 2200, ext. 5644

[email protected]

KEYWORDS: Europe United States North America New Jersey

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Logo
Logo
Posted on

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Splunk Inc.

NEW YORK, Dec. 04, 2020 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP is investigating potential claims against Splunk Inc. (“Splunk” or the “Company”) (NASDAQ: SPLK). The investigation focuses on the Company’s possible violations of federal securities laws.

On December 2, 2020, after the market closed, Splunk announced its third quarter 2021 financial results in a press release. The Company reported total revenue of $559 million, well below prior guidance expecting between $600 and $630 million. Splunk attributed the shortfall to “uncertainty and volatility for macro factors” that “cause[d] customers to delay spending commitments, particularly for high-value contracts.” However, analysts at BTIG wrote that this explanation “is fairly confusing given that most peers in the software space (and particularly in security software) saw relatively strong trends.” Also, analysts at JPMorgan were “blindsided by the magnitude of too many large deals slipping in the final days of October.”

On this news, Splunk’s stock price fell by $47.88 per share, or approximately 23%, to close at $158.03 per share on December 3, 2020.

If you purchased or otherwise acquired Splunk securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.


Kirby McInerney LLP
 is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
[email protected]



Posted on

RiverNorth Closed-End Funds Declare Year-End Capital Gain Distributions

RiverNorth Closed-End Funds Declare Year-End Capital Gain Distributions

CHICAGO–(BUSINESS WIRE)–
The RiverNorth Opportunistic Municipal Income Fund, Inc. and the RiverNorth Flexible Municipal Income Fund, Inc. have each declared a year-end capital gain distribution, as detailed below. These year-end capital gain distributions are in addition to each fund’s regular monthly distribution and are being paid to allow the funds to meet their 2020 distribution requirements for federal excise tax purposes.

Ex Date

Record Date

Payable Date

December 16, 2020

December 17, 2020

December 31, 2020

Ticker

Fund Name

Short-Term Capital Gain

Distribution Per Share

Long-Term Capital Gain

Distribution Per Share

RMI1

RiverNorth Opportunistic Municipal Income Fund, Inc.

$0.00000

$0.31355

Ticker

Fund Name

Short-Term Capital Gain

Distribution Per Share

 

Long-Term Capital Gain

Distribution Per Share

RFM1

RiverNorth Flexible Municipal Income Fund, Inc.

$0.22830

 

$0.04687

___________________________________________________________________________________

  1. RiverNorth does not provide tax advice; consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes as well as the AMT.

As of the date of this release, RiverNorth Managed Duration Municipal Income Fund, Inc., RiverNorth/DoubleLine Strategic Opportunity Fund, Inc., and RiverNorth Specialty Finance Corp. do not anticipate having to make a year-end capital gain distribution. Such determinations are based on then current estimates and are subject to change.

With each distribution that does not consist solely of net investment income, the respective Fund will issue a notice to shareholders and an accompanying press release that will provide detailed information regarding the amount and composition of the distribution and other related information. The amounts and sources of distributions reported in the notice to shareholders are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its full fiscal year and may be subject to changes based on tax regulations. Each Fund will send shareholders a Form 1099-DIV for the calendar year that will tell them how to report these distributions for federal income tax purposes.

Each Fund may at times distribute more than its net investment income and net realized capital gains; therefore, a portion of the distribution may result in a return of capital. A return of capital occurs when some or all of the money that shareholders invested in the Fund is paid back to them. A return of capital does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income.’ Any such returns of capital will decrease the Fund’s total assets and, therefore, could have the effect of increasing the Fund’s expense ratio. In addition, in order to make the level of distributions called for under its plan, the Fund may have to sell its portfolio securities at a less than opportune time.

About RiverNorth

RiverNorth Capital Management, LLC is an investment management firm founded in 2000. With $4.4 billion2 in assets under management as of October 31, 2020, RiverNorth specializes in opportunistic investment strategies in niche markets where the potential to exploit inefficiencies is greatest. RiverNorth is an institutional investment manager to registered funds, private funds and separately managed accounts.

This data is for information only and should not be construed as an official tax form, nor should it be considered tax or investment advice. RiverNorth is not a tax advisor and investors should consult a tax professional for guidance regarding their specific tax situation. When preparing your tax return, please refer to your Form 1099-DIV and consult your legal or tax advisor.

A portion of the distribution may be treated as paid from sources other than net income, including but not limited to short‐term capital gain, long‐term capital gain and return of capital.

Past performance is no guarantee of future results.

Investors should consider the Fund’s investment objective, risks, charges and expenses carefully before investing. The prospectus should be read carefully before investing. For more information, please read the prospectus, call your financial professional or call 844.569.4750.

The Funds referenced above are closed-end funds, and closed-end funds do not continuously issue shares for sale as open-end mutual funds do. Since the initial public offering periods have closed, each Fund now trades in the secondary market. Investors wishing to buy or sell shares need to place orders through an intermediary or broker. The share price of a closed-end fund is based on the market’s value.

Shares of closed-end investment companies frequently trade at a discount to their net asset value and initial offering price. The risk of loss due to this discount may be greater for initial investors expecting to sell their shares in a relatively short period after completion of the initial public offering.

Investments in the Funds are not appropriate for all investors and are not intended to be complete investment programs. The Funds are designed as a long-term investments and not as a trading vehicles.

Risk is inherent in all investing. Investing in any investment company security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part or all of your investment. Therefore, before investing in the common shares of a Fund, you should consider the risks as well as the other information in each Fund’s prospectus.

2Firm AUM reflects Managed Assets which includes the effects of leverage and investments in affiliated funds.

Chris Lakumb is a registered representative of ALPS Distributors, Inc.

Not FDIC Insured | May Lose Value | No Bank Guarantee

ALPS Distributors, Inc. is the FINRA Member Firm.

RiverNorth® is a registered trademark of RiverNorth Capital Management, LLC.

DoubleLine® is a registered trademark of DoubleLine Capital LP.

©2000-2020 RiverNorth Capital Management, LLC. All rights reserved.

RMI000183

Investor Contact

Chris Lakumb, CFA, CAIA

312.445.2336

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo
Posted on

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Interface, Inc. and Encourages Investors to Contact the Firm Before January 11, 2021

NEW YORK, Dec. 04, 2020 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired  Interface, Inc. (“Interface” or the “Company”) (NASDAQ: TILE) securities during the period from March 2, 2018 through September 28, 2020, both dates inclusive (the “Class Period”). Investors have until January 11, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Interface had inadequate disclosure controls, procedures, and internal control over financial reporting; (ii) consequently, Interface, inter alia, reported artificially inflated income and earnings per share (“EPS”) in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the Securities and Exchange Commission (“SEC”) with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On April 24, 2019, Defendants filed a current report on Form 8-K with the SEC, disclosing that Interface “received a letter in November 2017 from the [SEC] requesting that the Company voluntarily provide information and documents in connection with an investigation into the Company’s historical quarterly [EPS] calculations and rounding practices during the period 2014-2017”; that “[t]he Company subsequently received subpoenas from the SEC in February 2018, July 2018 and April 2019 requesting additional documents and information”; and that “[i]n the fourth quarter of 2018, the Company conducted at the SEC’s request an internal investigation into these and other related issues for seven quarters in 2015, 2016 and 2017.” On this news, Interface’s stock price fell $1.43 per share, or 8.37%, to close at $15.66 per share on April 25, 2019.

Then, on September 28, 2020, the SEC announced the conclusion of its investigation into Interface’s historical quarterly EPS calculations and rounding practices. Interface agreed to pay a $5 million fine to resolve the matter and was ordered to cease and desist from violating the federal securities laws. In the SEC’s enforcement order issued that same day, the SEC also disclosed how, inter alia, “Interface employees caused Interface to produce documents in response to Commission investigative requests that were suggestive of contemporaneous support for journal entries that, in truth, did not exist at the time the entries were recorded,” and had modified certain documents after the SEC’s investigation began. On this news, Interface’s stock price fell $0.20 per share, or 3.13%, over the following two trading sessions to close at $6.18 per share on September 29, 2020.

If you acquired Interface securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
[email protected]
www.kmllp.com



Posted on

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

Total gross proceeds from the offering to Cogent are approximately $115.0 million

PR Newswire

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 11,794,872 shares of its common stock at a public offering price of $9.75 per share. This includes the exercise in full by the underwriters of their 30-day option to purchase up to 1,538,461 additional shares of common stock. The aggregate proceeds to Cogent from the offering, after deducting the underwriting discounts and commissions and before estimated offering expenses, were approximately $108.1 million.

The net proceeds from the offering will be used for the continued development, regulatory and commercial preparation of PLX9486 to treat patients living with systemic mastocytosis and gastrointestinal stromal tumors (GIST).

Jefferies and Piper Sandler & Co. acted as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital and Ladenburg Thalmann also acted as co-managers for the offering.

The shares of common stock described above were offered by Cogent Biosciences, Inc. pursuant to a registration statement previously filed with the Securities and Exchange Commission (the “SEC”) that became effective on May 1, 2019. A final prospectus supplement and accompanying prospectus were filed with the SEC and available for free on the SEC’s website at http://www.sec.gov. Registration statements relating to the securities were filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”) and became effective on May 1, 2019. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. The offering was made only by means of a prospectus supplement and accompanying base prospectus. Copies of the final prospectus relating to the offering may be obtained from the SEC’s website at www.sec.gov or by request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; telephone: 877-821-7388; email: [email protected]): or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicolett Mall, J12SO3, Minneapolis Minnesota 55402, or by telephone at (800) 747-3924, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About 
Cogent Biosciences, Inc.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cogent-biosciences-announces-closing-of-upsized-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301186747.html

SOURCE Cogent Biosciences, Inc.